Anal Canal Cancer Clinical Practice Guidelines in Oncology

2005 ◽  
Vol 3 (4) ◽  
pp. 510 ◽  

An estimated 3,990 new cases of anal cancer will occur in 2005, accounting for approximately 1.6% of digestive system cancers in the United States. Prognosis directly depends on the size of the primary tumor and the likelihood of lymphatic spread, with tumors 2 cm or smaller cured in 80% of cases. The NCCN guidelines recommend a thorough evaluation for any patient with a suspicious lesion in the anal canal and include additional recommendations for diagnosis, treatment, and follow up for anal canal cancer. For the most recent version of the guidelines, please visit NCCN.org

2003 ◽  
Vol 1 (1) ◽  
pp. 64 ◽  

An estimated 3,900 new cases of anal canal cancer will occur in 2002, accounting for approximately 1.6% of digestive system cancers in the United States. NCCN clinical practice guidelines for managing anal cancer discuss the complete management of this disease, from clinical presentation through diagnosis, pathologic staging, surgical management, adjuvant treatment, management of recurrent and metastatic disease, and patient surveillance. For the most recent version of the guidelines, please visit NCCN.org


2003 ◽  
Vol 1 (2) ◽  
pp. 148 ◽  

The American Cancer Society estimates that approximately 205,000 new cases of breast cancer were diagnosed in the United States in the year 2002, and approximately 40,000 patients will die of this disease. The NCCN guidelines discuss the complex and varied therapeutic options for patients with noninvasive or invasive breast cancer. For the most recent version of the guidelines, please visit NCCN.org


2003 ◽  
Vol 1 (1) ◽  
pp. 94 ◽  

Hepatobiliary cancers are both common and highly lethal worldwide. However, in the United States, the incidence of hepatobiliary cancer is relatively low, with approximately 23,700 patients newly diagnosed each year. Gallbladder cancer is the most common of the hepatobiliary malignancies, accounting for approximately 30% of newly diagnosed cases in the United States. Along with summaries of the NCCN guidelines for the 4 subtypes of hepatobiliary cancer, this article includes a brief discussion of the epidemiology, pathology, etiology, staging, diagnosis, and treatment of each subtype. For the most recent version of the guidelines, please visit NCCN.org


2003 ◽  
Vol 1 (1) ◽  
pp. 28 ◽  

Carcinomas originating in the upper gastrointestinal tract constitute a major health problem around the world. In fact, experts estimate that approximately 34,700 new cases of upper gastrointestinal carcinomas and 25,000 deaths will have occurred in the United States in 2002. This article summarizes the NCCN clinical practice guidelines for managing gastric cancer, which portray uniformity in the systemic approach to cancer in the United States. The article also discusses anticipated future advances in the treatment of gastric carcinoma. For the most recent version of the guidelines, please visit NCCN.org


2004 ◽  
Vol 2 (6) ◽  
pp. 526 ◽  

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and the country's fourth most common cause of cancer mortality in women. In the year 2004, there will be an estimated 25,580 new diagnoses and an estimated 16,090 deaths from this neoplasm. The incidence increases with age and is most prevalent in the eighth decade of life, with an incidence rate of 57/100,000 women. The median age at the time of diagnosis is 63 years, and 70% of patients present with advanced disease. For the most recent version of the guidelines, please visit NCCN.org


2006 ◽  
Vol 4 (2) ◽  
pp. 102 ◽  
Author(s):  
_ _

Neuroendocrine tumors are relatively rare. An estimated 25,690 new cases of thyroid cancer will be diagnosed in the United States in 2005, accounting for approximately 1% of all malignancies. Neuroendocrine tumors can be broadly subdivided into tumors that are benign or malignant, functional (i.e., producing a syndrome of hormonal excess) or nonfunctional. The management of neuroendocrine tumors with surgical, medical, or radiation therapies is determined by the specific endocrine glands involved, aggressiveness and stage of the tumor, hormonal concentrations detected, and specific patient needs. These guidelines have been designed to address scenarios presented by 80% of patients and to avoid scenarios relevant to less than 5% of patients. For the most recent version of the guidelines, please visit NCCN.org


2005 ◽  
Vol 3 (3) ◽  
pp. 404 ◽  

In 2005, approximately 1,490 cancer deaths will occur among persons living with thyroid carcinoma in the United States. Interestingly, although thyroid carcinoma occurs more often in women, mortality rates are higher for men, probably because men are usually older at the time of diagnosis. The incidence of thyroid carcinoma increased almost 240% between 1950 and 2000, but mortality rates decreased more than 44%. Although the causes of these statistically significant changes are uncertain, the increasing incidence may be caused by the increase in radiation-induced thyroid carcinoma. Conversely, the decrease in mortality may be related to earlier diagnosis, when the disease is presumably more amenable to intervention. However, this conclusion is confounded by a possible lead time bias. For the most recent version of the guidelines, please visit NCCN.org


2019 ◽  
Vol 17 (2) ◽  
pp. 171-189 ◽  
Author(s):  
Erin Reid ◽  
Gita Suneja ◽  
Richard F. Ambinder ◽  
Kevin Ard ◽  
Robert Baiocchi ◽  
...  

As treatment of HIV has improved, people living with HIV (PLWH) have experienced a decreased risk of AIDS and AIDS-defining cancers (non-Hodgkin’s lymphoma, Kaposi sarcoma, and cervical cancer), but the risk of Kaposi sarcoma in PLWH is still elevated about 500-fold compared with the general population in the United States. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AIDS-Related Kaposi Sarcoma provide diagnosis, treatment, and surveillance recommendations for PLWH who develop limited cutaneous Kaposi sarcoma and for those with advanced cutaneous, oral, visceral, or nodal disease.


2006 ◽  
Vol 4 (5) ◽  
pp. 480 ◽  
Author(s):  
_ _

The lifetime risk of a woman developing breast cancer has increased over the past 5 years in the United States: of every 7 women, 1 is at risk based on a life expectancy of 85 years. An estimated 214,640 new cases (212,920 women and 1,720 men) of breast cancer and 41,430 deaths (40,970 women and 460 men) from this disease will occur in the United States in 2006. However, mortality from breast cancer has decreased slightly, attributed partly to mammographic screening. Early detection and accurate diagnosis made in a cost-effective manner are critical to a continued reduction in mortality. These practice guidelines are designed to facilitate clinical decision making. For the most recent version of the guidelines, please visit NCCN.org


Sign in / Sign up

Export Citation Format

Share Document